Gallo Pasquale, Condorelli Gianluigi
University La Sapienza, Rome, Italy.
Regen Med. 2006 Mar;1(2):183-94. doi: 10.2217/17460751.1.2.183.
Cell-based therapy is emerging as an innovative approach for the treatment of degenerative diseases, and stem cells appear to be an ideal source of cells for this. In cardiology, in particular, human embryonic stem cell (hESC)-derived cardiomyocytes theoretically fulfill most, if not all, of the properties of an ideal donor cell, but several critical obstacles need to be overcome. Many research projects are focusing on set-up strategies for directing hESC differentiation toward the cardiac lineage. It is one of the main difficulties in the search to provide a valuable source of cells to effect regeneration of myocardial tissue in patients with severe heart failure. To date, there are no easy and efficient protocols for the induction of hESC differentiation toward the cardiac lineage. Discovering new molecules or tools capable of doing this is imperative.
基于细胞的疗法正在成为治疗退行性疾病的一种创新方法，而干细胞似乎是用于此目的的理想细胞来源。特别是在心脏病学领域，理论上，人胚胎干细胞（hESC）衍生的心肌细胞即便不能完全具备理想供体细胞的所有特性，也能满足其中的大部分特性，但仍有几个关键障碍需要克服。许多研究项目都聚焦于引导hESC向心脏谱系分化的建立策略。这是为重症心力衰竭患者提供有价值的细胞来源以实现心肌组织再生的研究中的主要困难之一。迄今为止，尚无简单有效的方案可诱导hESC向心脏谱系分化。因此，发现能够做到这一点的新分子或工具势在必行。
